Questions to ask oncologist on first visit

This is rather long and from an AI search, but I hope it is helpful:
You’re stepping into a conversation that absolutely deserves clarity, control, and a sense of partnership with the oncologist. With muscle‑invasive bladder cancer, stage T2, node‑positive (N1), the treatment pathway becomes more complex — and the quality of the discussion with the oncologist can directly shape outcomes and peace of mind.
A strong approach is to organize your questions into five domains: diagnosis, treatment options, risks/benefits, logistics, and long‑term planning. This gives you a structured, confident way to guide the appointment.

🧭 Essential Questions for the Oncologist
🩺 1. Understanding the Diagnosis
- What does T2, N1 mean in my husband’s specific case?
- How confident are we about the N1 finding — was it based on imaging or biopsy?
- Are there any additional tests needed to confirm staging (e.g., PET‑CT, MRI, repeat TURBT pathology review)?

💉 2. Treatment Options and Rationale
- What treatment plan do you recommend for T2, N1 disease, and why?
- Is neoadjuvant chemotherapy recommended before any local treatment?
- Should we consider chemoradiation instead of surgery, or is radical cystectomy the preferred path?
- Are there immunotherapy options appropriate for node‑positive disease?
- Is my husband eligible for any clinical trials?

⚖️ 3. Effectiveness, Risks, and Side Effects
- What are the expected outcomes for the recommended treatment?
- How does node‑positive disease affect prognosis?
- What are the short‑term and long‑term side effects of the proposed therapy?
- How will treatment affect daily life, energy, continence, sexual function, and independence?
- How do we manage side effects proactively?

🧪 4. Pathology and Molecular Information
- Should we request a second pathology review of the TURBT specimen?
- Are there molecular markers (e.g., FGFR, PD‑L1) that could influence treatment choices?
- Is genomic testing of the tumor recommended?

🧍‍♂️ 5. Surgical or Radiation Considerations
If surgery is on the table:
- What type of urinary diversion is recommended (ileal conduit, neobladder, continent reservoir)?
- What is the surgeon’s experience and complication rate?
- How long is recovery, and what support will he need?
If chemoradiation is an option:
- What is the likelihood of bladder preservation?
- How do outcomes compare to surgery for N1 disease?

🧩 6. Coordination of Care
- Who will be the point person for questions during treatment?
- How often will imaging be done to monitor response?
- How do we know if treatment is working?
- What happens if the cancer does not respond as expected?

🧘‍♂️ 7. Quality of Life and Support
- What resources are available for nutrition, physical therapy, and emotional support?
- Are there programs for caregiver support?
- How can we maintain strength and function during treatment?

📅 8. Timing and Urgency
- How quickly should treatment begin?
- Is there any harm in taking a short time to get a second opinion?

🧭 9. Second Opinions and Multidisciplinary Review
- Will this case be reviewed by a tumor board?
- Which major centers would you recommend for a second opinion?

🧠 A final thought
You’re doing exactly what a strong advocate does — preparing, organizing, and making sure nothing gets missed. With node‑positive MIBC, the treatment plan needs to be deliberate and personalized, and these questions help ensure you get a clear, evidence‑based roadmap.

1. Diagnosis

A: Node-positive (N1) disease is the main driver of risk. T2 alone is generally curable with surgery, but once nodes are involved, systemic therapy is critical.
B: N1 is usually diagnosed via imaging (CT, MRI, PET) or biopsy. If it’s just radiographic, it’s still clinically significant.
C: Tumor genomic profiling (Tempus, Caris, Altera, Foundation) can identify actionable mutations or trial eligibility. It doesn’t change first-line NAC for most patients but helps for high-risk or refractory cases.

2. Treatment Options
A: Neoadjuvant chemotherapy (NAC) is standard for MIBC before radical cystectomy (RC). Common regimens:
GC (gemcitabine + cisplatin)
ddMVAC (dose-dense methotrexate, vinblastine, doxorubicin, cisplatin)
B: Progression risk on NAC: About 40% of patients with N1 disease progress before surgery. This is established in retrospective and pooled analyses — it’s not anecdotal. Some tumors grow, new nodes appear, or micrometastatic disease emerges despite chemo.
C: Surgery vs. bladder preservation: For N1, RC is still the mainstay. Bladder-sparing chemoradiation is possible in highly selected cases, but N1 disease significantly reduces success rates.
D: Immunotherapy is now standard in several contexts: Nivolumab adjuvant for high-risk patients after RC (CheckMate-274) PD-L1 status may guide trial eligibility but is not an absolute predictor
CTDNA (Signatera) can help detect minimal residual disease and guide adjuvant therapy decisions

E: Clinical trials (clinicaltrials.gov, BCAN, CancerCommons) may offer novel combinations, but eligibility criteria are strict.
3. Effectiveness & Side Effects
A: Outcomes are variable: some patients achieve complete remission; others relapse. N1 disease historically recurs in ~70% of patients, even with RC ± NAC.
B: Side effects depend on therapy:
Chemo: fatigue, nausea, neuropathy, hair loss, myelosuppression
Immunotherapy: immune-related adverse events (colitis, hepatitis, endocrinopathies, pneumonitis, skin rash). Severity varies; sometimes mild, sometimes life-threatening.
C: Daily life and function impact are highly individual; early planning for nutrition, mobility, and urostomy care is crucial.

4. Pathology & Molecular Testing
A: Second pathology review is optional; major centers usually do internal verification.
B: Molecular markers (PD-L1, FGFR, others) can influence trial or targeted therapy selection. Requesting slides, waiting for these to arrive, reimaging and so on all take a lot of time. Meanwhile the disease progresses and spreads.
C: Genomic profiling is useful for high-risk or recurrent disease; it may not change first-line NAC for most patients.

5. Surgery or Radiation
A: Urinary diversion type (ileal conduit, neobladder, continent reservoir) depends on anatomy, patient preference, and surgeon expertise.
B: Complications vary; surgical mortality is ~1–2% at high-volume centers.
C: Hospital stay is usually 5–10 days for uncomplicated RC.
D: Radiation-based bladder preservation in N1 disease has lower long-term success; lifelong monitoring is mandatory.

6. Care Coordination
A: Centers differ — some have dedicated coordinators; in other systems, patients/caregivers must track appointments, labs, and imaging.
B: Follow-up imaging is generally every 3–6 months initially.
C: CTDNA or other biomarkers may help assess response, but absence of detectable disease doesn’t guarantee cure.
D: If disease progresses, options include switching systemic therapy, immediate surgery if feasible, or enrollment in trials.

7. Quality of Life & Support
A: Nutrition, physical therapy, and mental health support improve outcomes and tolerance to therapy.
B: Patient communities like this one offer practical and emotional support.
C: Maintaining activity, good protein intake, and social engagement helps tolerance to treatment.

8. Timing & Urgency
A: MIBC with N1 disease is aggressive; treatment should start promptly. Short delays for second opinions are acceptable but should not be prolonged. With aggressive subtypes this is high risk.

9. Second Opinions
A: Most N1 MIBC cases are straightforward for tumor boards; second opinions are still valuable for confirmation and access to trials.
B: High-volume, NCI-designated centers with board-certified experts and publication history are best.

Bottom Line:
N1 MIBC is high-risk: ~70% recurrence after surgery historically.
NAC has ~40% progression risk for N1; careful monitoring is essential. Or cut it out ASAP and bomb any lingering cells afterwards.
Adjuvant chemo or immunotherapy can improve outcomes but is not a guarantee.
CTDNA and molecular profiling help guide therapy selection and trial enrollment.
Decisions must be personalized, evidence-based, and very timely.

Thank you for a thorough response!

@gemdoc25 thank you so much.

@jaxfl, it looks like you found this information with the help of an AI assistant like ChatGPT. I agree that AI tools can be helpful. Keep in mind, however, that AI tools can sound sure, even when they’re wrong.

If you share information from AI tools with the Mayo Clinic Connect community, please follow the guidance provided in the Community Guidelines https://connect.mayoclinic.org/blog/about-connect/tab/community-guidelines/.

You are responsible for the accuracy, originality and quality of your posts, whether a tool helped you or not. Here’s how to use AI the right way:
- Start with your own story and ideas. AI can add information but not replace you.
- If you use AI, use short AI quotes to back up your experience, not long AI essays.
- Do not use AI answers alone.
- Be open about your AI help. Say what question you asked or what prompt you used.

See more tips here:
- What is Generative AI? What does this mean on Mayo Clinic Connect? https://connect.mayoclinic.org/blog/about-connect/newsfeed-post/what-is-generative-ai-artificial-intelligence-what-does-this-mean-on-mayo-clinic-connect/

I actually wrote everything and then put it in AI. Thank you for the Mayo AI guidance.

@jaxfl, nice! That's a great use of AI.

Yes. But sometimes I wonder if my own observations are not more precise. AI makes lots of mistakes.